Mostrar el registro sencillo del ítem
dc.contributor.author
Masson, Walter
dc.contributor.author
Lobo, Martín
dc.contributor.author
Siniawski, Daniel
dc.contributor.author
Molinero, Graciela
dc.contributor.author
Huerín, Melina
dc.contributor.author
Nogueira, Juan Patricio
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2022-01-31T14:43:17Z
dc.date.issued
2019-08
dc.identifier.citation
Masson, Walter; Lobo, Martín; Siniawski, Daniel; Molinero, Graciela; Huerín, Melina; et al.; Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis; Springer; High Blood Pressure and Cardiovascular Prevention; 26; 4; 8-2019; 263-272
dc.identifier.issn
1120-9879
dc.identifier.uri
http://hdl.handle.net/11336/150977
dc.description.abstract
Introduction: Previous report showed that more intensive lipid-lowering therapy was associated with less mortality when baseline LDL-C levels were > 100 mg/dL. Non-HDL-C is a better predictor of cardiovascular risk than simpler LDL-C. Aim: The objective of this meta-analysis was to define the impact of lipid-lowering therapy on the reduction of total and cardiovascular mortality by different baseline levels of non-HDL-C. Methods: We performed a meta-analysis including randomized, controlled clinical trials of lipid-lowering therapy, reporting mortality with a minimum of 6 months of follow-up, searching in PubMed/Medline, EMBASE and Cochrane Clinical Trials databases. The random-effects model and meta-regression were performed. Results: Twenty nine trials of lipid-lowering drugs, including 233,027 patients, were considered eligible for the analyses. According to the baseline non-HDL-C level, the results on cardiovascular mortality were: (1) ≥ 190 mg/dL: OR 0.63 (95% CI 0.53–0.76); (2) 160–189 mg/dL: OR 0.82 (95% CI 0.75–0.89); (3) 130–159 mg/dL: OR 0.71 (95% CI 0.52–0.98); (4) < 130 mg/dL: OR 0.95 (95% CI 0.87–1.05). When evaluating mortality from any cause, the results were the following: (1) ≥ 190 mg/dL: OR 0.70 (95% CI 0.61–0.82); (2) 160–189 mg/dL: OR 0.91 (95% CI 0.83–0.98); (3) 130–159 mg/dL; OR 0.88 (95% CI 0.77–1.00); (4) < 130 mg/dL: OR 0.98 (95% CI 0.91–1.06). The meta-regression analysis showed a significant association between baseline non-HDL-C and mortality.
Conclusions
In these meta-analyses, lipid-lowering therapy was associated with reduction in the risk of all-cause and cardiovascular mortality when baseline non-HDL-C levels were above than 130 mg/dL.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
LIPID-LOWERING THERAPY
dc.subject
META-ANALYSIS
dc.subject
MORTALITY
dc.subject
NON-HDL-CHOLESTEROL
dc.subject.classification
Endocrinología y Metabolismo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-07-30T18:50:18Z
dc.identifier.eissn
1179-1985
dc.journal.volume
26
dc.journal.number
4
dc.journal.pagination
263-272
dc.journal.pais
Suiza
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Viena
dc.description.fil
Fil: Masson, Walter. Federacion Argentina de Cardiologia; Argentina. Sociedad Argentina de Lípidos; Argentina. Hospital Italiano; Argentina
dc.description.fil
Fil: Lobo, Martín. Federacion Argentina de Cardiologia; Argentina
dc.description.fil
Fil: Siniawski, Daniel. Hospital Italiano; Argentina. Sociedad Argentina de Lípidos; Argentina. Federacion Argentina de Cardiologia; Argentina
dc.description.fil
Fil: Molinero, Graciela. Federacion Argentina de Cardiologia; Argentina
dc.description.fil
Fil: Huerín, Melina. Federacion Argentina de Cardiologia; Argentina
dc.description.fil
Fil: Nogueira, Juan Patricio. Sociedad Argentina de Lípidos; Argentina. Universidad Nacional de Formosa; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
dc.journal.title
High Blood Pressure and Cardiovascular Prevention
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40292-019-00330-8
Archivos asociados